Immunogenicity of Human Mesenchymal Stem Cells in HLA-Class I-Restricted T-Cell Responses Against Viral or Tumor-Associated Antigens
Open accessThe DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
Human mesenchymal stem cells (MSC) are immunosuppressive and poorly immunogenic but may act as antigen-presenting cells (APC) for CD4+ T-cell responses; here we have investigated their ability to serve as APC for in vitro CD8+ T-cell responses. MSC pulsed with peptides from viral antigens evoked interferon (IFN)-γ and Granzyme B secretion in specific cytotoxic T lymphocytes (CTL) and were lysed, although with low efficiency. MSC transfected with tumor mRNA or infected with a viral vector carrying the Hepatitis C virus NS3Ag gene induced cytokine release but were not killed by specific CTL, even following pretreatment with IFN-γ. To investigate the mechanisms involved in MSC resistance to CTL-mediated lysis, we analyzed expression of human leukocyte antigen (HLA) class I-related antigen-processing machinery (APM) components and of immunosuppressive HLA-G molecules in MSC. The LMP7, LMP10, and ERp57 components were not expressed and the MB-1 and zeta molecules were downregulated in MSC either unmanipulated or pretreated with IFN-γ. Surface HLA-G was constitutively expressed on MSC but was not involved in their protection from CTL-mediated lysis. MSC supernatants containing soluble HLA-G (sHLA-G) inhibited CTL-mediated lysis, whereas those lacking sHLA-G did not. The role of sHLA-G in such inhibition was unambiguously demonstrated by partial restoration of lysis following sHLA-G depletion from MSC supernatants. In conclusion, human MSC can process and present HLA class I-restricted viral or tumor antigens to specific CTL with a limited efficiency, likely because of some defects in APM components. However, they are protected from CTL-mediated lysis through a mechanism that is partly sHLA-G-dependent. Disclosure of potential conflicts of interest is found at the end of this article.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Dominici, M., Le Blanc, K., Mueller, I., Slaper-Cortenbach, I., Marini, F. C., Krause, D. S., Deans, R. J., Keating, A., Prockop, D. J., & Horwitz, E. M. (2006) · Cytotherapy · doi:10.1080/14653240600855905 · Cited by 17,766
Human mesenchymal stem cells modulate allogeneic immune cell responses
Aggarwal, S., & Pittenger, M. F. (2005) · Blood · doi:10.1182/blood-2004-04-1559 · Cited by 4,511
Di Nicola, M., Carlo-Stella, C., Magni, M., Milanesi, M., Longoni, P. D., Matteucci, P., Grisanti, S., & Gianni, A. M. (2002) · Blood · doi:10.1182/blood.v99.10.3838 · Cited by 3,226
Mesenchymal stem cells within tumour stroma promote breast cancer metastasis
Karnoub, A. E., Dash, A. B., Vo, A. P., Sullivan, A., Brooks, M. W., Bell, G. W., Richardson, A. L., Polyak, K., Tubo, R., & Weinberg, R. A. (2007) · Nature · doi:10.1038/nature06188 · Cited by 3,206
Le Blanc, K., Rasmusson, I., Sundberg, B., Götherström, C., Hassan, M., Uzunel, M., & Ringdén, O. (2004) · The Lancet · doi:10.1016/s0140-6736(04)16104-7 · Cited by 2,734
Human mesenchymal stem cells exert potent antitumorigenic effects in a model of Kaposi's sarcoma
Khakoo, A. Y., Pati, S., Anderson, S. A., Reid, W., Elshal, M. F., Rovira, I. I., Nguyen, A. T., Malide, D., Combs, C. A., Hall, G., et al. (2006) · The Journal of Experimental Medicine · doi:10.1084/jem.20051921 · Cited by 747
Ramasamy, R., Lam, E. W.-F., Soeiro, I., Tisato, V, Bonnet, D., & Dazzi, F. (2007) · Leukemia · doi:10.1038/sj.leu.2404489 · Cited by 404
Cited by
Mesenchymal stem cells in health and disease
Uccelli, A., Moretta, L., & Pistoia, V. (2008) · Nature Reviews Immunology · doi:10.1038/nri2395 · Cited by 3,746
Self-citationFracture healing: mechanisms and interventions
Einhorn, T. A., & Gerstenfeld, L. C. (2015) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2014.164 · Cited by 1,807
Mesenchymal stem cells: environmentally responsive therapeutics for regenerative medicine
Murphy, M. B., Moncivais, K., & Caplan, A. I. (2013) · Experimental & Molecular Medicine · doi:10.1038/emm.2013.94 · Cited by 1,231
Multipotent mesenchymal stromal cells and the innate immune system
Le Blanc, K., & Mougiakakos, D. (2012) · Nature Reviews Immunology · doi:10.1038/nri3209 · Cited by 1,018
Ethical and Safety Issues of Stem Cell-Based Therapy
Volarevic, V., Markovic, B. S., Gazdic, M., Volarevic, A., Jovicic, N., Arsenijevic, N., Armstrong, L., Djonov, V., Lako, M., & Stojkovic, M. (2018) · International Journal of Medical Sciences · doi:10.7150/ijms.21666 · Cited by 876
Immune modulation by mesenchymal stem cells
Jiang, W., & Xu, J. (2020) · Cell Proliferation · doi:10.1111/cpr.12712 · Cited by 650
Apoptosis in mesenchymal stromal cells induces in vivo recipient-mediated immunomodulation
Galleu, A., Riffo-Vasquez, Y., Trento, C., Lomas, C., Dolcetti, L., Cheung, T. S., von Bonin, M., Barbieri, L., Halai, K., Ward, S., et al. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aam7828 · Cited by 646
Mesenchymal stem cells: Emerging mechanisms of immunomodulation and therapy
Glenn, J. D. (2014) · World Journal of Stem Cells · doi:10.4252/wjsc.v6.i5.526 · Cited by 406
Blazquez, R., Sanchez-Margallo, F. M., de la Rosa, O., Dalemans, W., Ãlvarez, V., Tarazona, R., & Casado, J. G. (2014) · Frontiers in Immunology · doi:10.3389/fimmu.2014.00556 · Cited by 376
The immunomodulatory capacity of mesenchymal stem cells
Gebler, A., Zabel, O., & Seliger, B. (2012) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2011.10.004 · Cited by 365
Golpanian, S., Wolf, A., Hatzistergos, K. E., & Hare, J. M. (2016) · Physiological Reviews · doi:10.1152/physrev.00019.2015 · Cited by 343
Regmi, S., Pathak, S., Kim, J. O., Yong, C. S., & Jeong, J.-H. (2019) · European Journal of Cell Biology · doi:10.1016/j.ejcb.2019.04.002 · Cited by 314
Treatment of Inflammatory Diseases with Mesenchymal Stem Cells
Newman, R., Yoo, D., LeRoux, M., & Danilkovitch-Miagkova, A. (2009) · Inflammation & Allergy - Drug Targets · doi:10.2174/187152809788462635 · Cited by 308
Potential implications of mesenchymal stem cells in cancer therapy
Dai, L.-J., Moniri, M. R., Zeng, Z.-R., Zhou, J. X., Rayat, J., & Warnock, G. L. (2011) · Cancer Letters · doi:10.1016/j.canlet.2011.02.012 · Cited by 99
“totoxicity [126,127]”
Ma, Y., Hao, X., Zhang, S., & Zhang, J. (2012) · Breast Cancer Research and Treatment · doi:10.1007/s10549-011-1774-x · Cited by 85
Review of Mesenchymal Stem Cells and Tumors: Executioner or Coconspirator?
Feng, B., & Chen, L. (2009) · Cancer Biotherapy and Radiopharmaceuticals · doi:10.1089/cbr.2009.0652 · Cited by 83
“14 Exosomes are 30–100-nm vesicles secreted by a wide range of mammalian cell types after fusion of the multivesicular body (MVB) and the cell membrane.”
Mesenchymal stem cell therapy as a game-changer in liver diseases: review of current clinical trials
Huang, W.-C., Li, Y.-C., Chen, P.-X., Ma, K. S.-K., & Wang, L.-T. (2025) · Stem Cell Research & Therapy · doi:10.1186/s13287-024-04127-y · Cited by 29
Metadata
- Authors
- Morandi, F., Raffaghello, L., Bianchi, G., Meloni, F., Salis, A., Millo, E., Ferrone, S., Barnaba, V., & Pistoia, V.
- Venue
- Stem Cells
- Publisher
- Oxford University Press (OUP)
- Published
- 2008-02-21
- Volume
- 26
- Issue
- 5
- Pages
- 1275-1287
- ISSN
- 1066-5099 (ISSN-L)
- 1549-4918
- OpenAlex
- W2008055490
- Cited by
- 153
- References
- 7
- FWCI
- 5.09
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.